Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to predict chemo risks for seniors with breast cancer

NCT ID NCT01472094

Knowledge-focused Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is looking for ways to predict which older adults (age 65 and up) with early-stage breast cancer are more likely to have serious side effects from chemotherapy. Researchers will collect medical information and blood samples from 700 participants to build a model that could help doctors tailor treatments. The goal is to reduce harm and improve quality of life for older cancer patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors predict which older adults are at higher risk for chemotherapy side effects, allowing for safer, more personalized treatment plans.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to immediate changes in care, and the findings might not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 700 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2011

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Outpatient clinic practices (City of Hope, Memorial Sloan-Kettering Cancer Center, Yale University School of Medicine, University of Rochester, University of North Carolina, Wake Forest University, and Case Western Reserve University)

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Patients with Breast Cancer: Inclusion Criteria: * Patients with stages I-III breast cancer receiving adjuvant or neoadjuvant chemotherapy * Able to understand English * Able to provide informed consent * Patients age ≥65 and of any performance status are eligible Exclusion Criteria: * Patients with metastatic disease Breast Cancer Controls: Inclusion Criteria: * Patients with stages I-III breast cancer * Patient will not receive adjuvant or neoadjuvant chemotherapy * Patients age ≥65 and of any performance status are eligible * Able to understand English * Able to provide informed consent Exclusion Criteria: * Patients with metastatic disease * Receipt of chemotherapy Healthy Controls: Inclusion Criteria: * Patients age ≥65 and of any performance status are eligible * No history of cancer (excluding non-melanoma skin cancer) * Able to understand English * Able to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • Case Western Reserve University

    Cleveland, Ohio, 44106, United States

  • City of Hope Medical Center

    Duarte, California, 91010, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

  • Hofstra-North-LIJ Cancer Institute

    New Hyde Park, New York, 11042, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Memorial Sloan-Kettering Cancer Center

    New York, New York, 10065, United States

  • Rhode Island Hospital

    Providence, Rhode Island, 02903, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

  • Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • University of North Carolina

    Chapel Hill, North Carolina, 27514, United States

  • University of Rochester Medical Center

    Rochester, New York, 14642, United States

  • University of Virginia Health System

    Charlottesville, Virginia, 22903, United States

  • Wake Forest University

    Winston-Salem, North Carolina, 27106, United States

  • Washington University St. Louis

    St Louis, Missouri, 63110, United States

  • Yale University

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.